ArticleHealth science reports2026
Competing Risk Survival Analysis of Time to In-Hospital Recovery or Death Among COVID-19 Patients: A Hospital-Based Multicenter Retrospective Cohort Study in Southeast Ethiopia.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: In-hospital death and recovery are competing risks in COVID-19 patients, complicating prognosis. While international prognostic scores exist, their reliance on complex biomarkers limits their utility in resource-constrained settings. This study aimed to estimate the duration and identify determinants of in-hospital outcomes in southeast Ethiopia and to develop a clinically accessible risk stratification tool. Methods: Data from 827 confirmed COVID-19 patients (October 2022-May 2023) across six treatment centers were analyzed using the Fine-Gray Competing Risk Survival Analysis (CRSA). Additionally, a novel "Asella COVID-19 Risk Score" was developed using readily available bedside clinical parameters (age, comorbidity, and antibiotic use) and validated using receiver operating characteristic analysis. Results: Overall, 139/827 (17%) died, and 516/827 (62%) recovered. Risk of death was significantly higher for patients aged ≥ 50 years (acsHR = 2.62; 95%CI: 1.29, 5.29; Conclusion: Advanced age and immunocompromised status significantly increase mortality risk. The Asella COVID-19 Risk Score provides a clinically validated, high-NPV triage tool suitable for resource-limited settings, facilitating the early identification of high-risk patients and more efficient resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.